Front Burner is a daily news podcast that takes you deep into the stories shaping Canada and the world. Each morning, from Monday to Friday, host Jayme Poisson talks with the smartest people covering the biggest stories to help you understand what’s going on.
Front Burner is a daily news podcast that takes you deep into the stories shaping Canada and the world. Each morning, from Monday to Friday, host Jayme Poisson talks with the smartest people covering the biggest stories to help you understand what’s going on.
It's estimated that as many as 10 per cent of adults in Canada use a GLP-1 type drug like Ozempic. The prescription medicine is used for type 2 diabetes management and increasingly prescribed off-label for weight loss. And this month, for the first time, the World Health Organization has conditionally recommended GLP-1 drugs for the long-term treatment of obesity.
But while these drugs have been called a game-changing tool to manage a complex and stigmatized health condition, there’s also a lot of questions about the potential negative impact.
With Ozempic’s patent set to expire soon in Canada, and more affordable generic options about to hit the market, a lot more people you know could end up on a weight-loss drug.
Today we bring you the rise and risks of GLP-1s with help from Dylan Scott. He is a Senior Correspondent at Vox who covers health.
For transcripts of Front Burner, please visit: https://www.cbc.ca/radio/frontburner/transcripts